<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RADIOGARDASE- ferric ferrocyanideÂ capsuleÂ </strong><br>Heyl Chem.-pharm. Fabrik GmbH &amp; Co. KG<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">RADIOGARDASE</span> safely and effectively.  See full prescribing information for <span class="Bold">RADIOGARDASE</span>.<br><br><span class="Bold">RADIOGARDASE<span class="Sup"></span>(prussian blue insoluble) capsules, for oral use </span><br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Radiogardase is a decorporation agent, indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination (<a href="#ID_804c5276-dadf-482b-a314-84d8227fc7c0">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Adults and Adolescents: 3 grams orally three times a day (<a href="#ID_2cbf39d8-af8e-435f-b8f8-a310978ba85d">2.3</a>)</dd>
<dt>â€¢</dt>
<dd>Pediatrics (2 â€“ 12 years): 1 gram orally three times a day (<a href="#ID_2cbf39d8-af8e-435f-b8f8-a310978ba85d">2.3</a>)</dd>
<dt>â€¢</dt>
<dd>Administer as soon as possible after internal contamination with cesium or thallium is suspected (<a href="#ID_d8befe1d-6fdb-403d-ac62-c10232ab54ae">2.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 0.5 grams (<a href="#ID_9c6d1e41-6686-4094-890a-891ce6e0ef06">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#ID_efbdfbc0-b54f-44a0-9e6f-1792dc060fdd">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Underline">Increased radiation absorbed dose to gastrointestinal mucosa</span>: Monitor for decreased gastrointestinal motility (<a href="#ID_41140557-bdfa-48b3-b04f-333c6ad0a312">5.1</a>) </dd>
<dt>â€¢</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span>: Monitor and treat (<a href="#ID_75ecb1f4-1984-4099-aa3f-c6c8c9df9bb9">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Electrolyte abnormalities</span>: Monitor serum electrolytes during treatment (<a href="#ID_9fc35059-d153-418f-9e05-59c65e862500">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Blue discoloration of stool, oral mucosa and dentition</span>  (<a href="#ID_bf7ec60b-1678-41ee-8c4d-620f99e7e8ef">5.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction (incidence &gt;24%) was <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (<a href="#ID_0d2821cd-7c18-47c3-b5ca-9cf307edc23f">6</a>)<br>Â Â Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">info@heyl-berlin.de, Fax +49 30 817 4049</span><span class="Bold"> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Important Administration Instructions</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Decontamination Procedures for Radioactive Cesium or Thallium Contamination</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Recommended Dosage</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Treatment of Radioactive Cesium Contamination</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Treatment of Radioactive and Non-radioactive Thallium Contamination</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Increased Radiation Absorbed Dose to Gastrointestinal Mucosa</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Electrolyte Abnormalities</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Blue Discoloration of Feces, Oral Mucosa, and Dentition</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Cesium-137 Contamination</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Thallium Contamination</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_804c5276-dadf-482b-a314-84d8227fc7c0"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium, in order to increase their rates of elimination.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_87a01453-3919-4107-9bec-4f0c0459f04f"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d8befe1d-6fdb-403d-ac62-c10232ab54ae"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Important Administration Instructions</span></h2>
<dl>
<dt>â€¢</dt>
<dd>Obtain quantitative baseline of the internalized contamination by radioactive cesium (137Cs) and/or thallium by appropriate whole-body counting and/or by bioassay (e.g., biodosimetry), or feces/urine samples, whenever possible prior to Radiogardase treatment.</dd>
<dt>â€¢</dt>
<dd>Initiate treatment with Radiogardase as soon as possible after contamination is suspected.  Even when delayed, treatment with Radiogardase is effective and should not be withheld. </dd>
<dt>â€¢</dt>
<dd>Take Radiogardase capsules with food to stimulate excretion of cesium or thallium. </dd>
<dt>â€¢</dt>
<dd>In patients who cannot tolerate swallowing large numbers of capsules, open the capsules and mix with bland food or liquids. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4dc3a27a-a290-4b16-95c0-9409f08f4a80"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Decontamination Procedures for Radioactive Cesium or Thallium Contamination</h2>
<p class="First">Prior to initiating treatment with Radiogardase, follow radioactive decontamination safety procedures including:</p>
<dl>
<dt>â€¢</dt>
<dd>Use appropriate radiation protective attire and closely monitor personnel and treatment area for radiation levels using radiation detection, indication, and computation devices (RADIAC) or thermal luminescent devices (TLD).</dd>
<dt>â€¢</dt>
<dd>Control spread of radiation contamination through the establishment of a patient decontamination area and a contaminated material disposal site (with proper labeling, handling, and disposal of contaminated material).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2cbf39d8-af8e-435f-b8f8-a310978ba85d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Recommended Dosage</h2>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Underline">Adults and Adolescents</span>:  3 grams (6 capsules) taken orally three times a day (a total daily dose of 9 grams)</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Pediatric Patients (2 â€“ 12 years)</span>: 1 gram (2 capsules) taken orally three times a day (a total daily dose of 3 grams)</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_29aefa34-7c38-4b67-85ff-7e3b3d1c361e"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Treatment of Radioactive Cesium Contamination</h2>
<dl>
<dt>â€¢</dt>
<dd>Anticipate that treatment with Radiogardase may last 30 days or longer.</dd>
<dt>â€¢</dt>
<dd>Base duration of Radiogardase treatment on weekly measurements of radioactivity in urine and fecal samples to monitor cesium elimination rate.  </dd>
<dt>â€¢</dt>
<dd>Obtain weekly laboratory evaluations (complete blood count, serum chemistry and electrolytes). </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9a9d5a3c-ecd3-440b-86e2-8667acb1ed59"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Treatment of Radioactive and Non-radioactive Thallium Contamination</h2>
<dl>
<dt>â€¢</dt>
<dd>Anticipate that treatment with Radiogardase may last 30 days or longer.</dd>
<dt>â€¢</dt>
<dd>For radioactive thallium: <dl>
<dt>o</dt>
<dd>Base duration of Radiogardase treatment on weekly measurements of radioactivity  inurine and fecal samples to monitor thallium elimination rate.</dd>
<dt>o</dt>
<dd>Continue Radiogardase treatment until a 24-hour urine thallium test is normal (less than 5 micrograms per liter) and radiation level is acceptable.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>For non-radioactive thallium: Continue Radiogardase treatment until a 24-hour urine thallium test is normal (less than 5 micrograms per liter).</dd>
<dt>â€¢</dt>
<dd>Obtain weekly laboratory evaluations (complete blood count, serum chemistry and electrolytes).</dd>
<dt>â€¢</dt>
<dd>In cases of severe thallium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, additional types of treatment may be necessary, such as: <dl>
<dt>o</dt>
<dd>Induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, followed by gastric intubation and lavage</dd>
<dt>o</dt>
<dd>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> until urinary thallium excretion is less than 1 mg/24 hours</dd>
<dt>o</dt>
<dd>Charcoal hemoperfusion may be useful during the first 48 hours after thallium ingestion (biodistribution phase).</dd>
<dt>o</dt>
<dd>Hemodialysis has also been reported to be effective in thallium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</dd>
</dl>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_9c6d1e41-6686-4094-890a-891ce6e0ef06"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules:  0.5 grams - dark blue capsule is imprinted with the light blue inscription: <span class="Sub"></span><a name="id-183597761"></a><img alt="Heyl imprint image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-01.jpg">  PB</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_efbdfbc0-b54f-44a0-9e6f-1792dc060fdd"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_14024cac-5fda-4e8d-946c-abd2d2133d36"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_41140557-bdfa-48b3-b04f-333c6ad0a312"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Increased Radiation Absorbed Dose to Gastrointestinal Mucosa</h2>
<p class="First">Radiogardase can decrease gastrointestinal motility, thus slowing the transit time of radioactivity in the gastrointestinal tract. The slowed transit time can increase the radiation absorbed dose to the gastrointestinal mucosa.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75ecb1f4-1984-4099-aa3f-c6c8c9df9bb9"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First">Radiogardase can cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.  Monitor and treat for signs and symptoms of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.  Patients with disorders associated with decreased gastrointestinal motility are at higher risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9fc35059-d153-418f-9e05-59c65e862500"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Electrolyte Abnormalities</h2>
<p class="First">Radiogardase may bind to electrolytes found in the gastrointestinal tract. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, with serum potassium values of 2.5 â€“ 2.9 (normal 3.5 â€“ 5.0), was reported in 3 (7%) of 42 patients during treatement  with Radiogardase. Monitor serum electrolytes during Radiogardase treatment, particularly when treating patients with pre-existing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf7ec60b-1678-41ee-8c4d-620f99e7e8ef"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Blue Discoloration of Feces, Oral Mucosa, and Dentition</h2>
<p class="First">Radiogardase is excreted primarily in feces and turns stools blue.  When Radiogardase capsules are opened and the contents eaten with food, the oral mucosa and dentition may also be colored blue.   </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_0d2821cd-7c18-47c3-b5ca-9cf307edc23f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> was reported in 10 (24%) of 42 patients treated with Radiogardase. Severity of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was mild in 7 patients and moderate in 3 patients <span class="Italics">[see <a href="#ID_75ecb1f4-1984-4099-aa3f-c6c8c9df9bb9">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_64478a19-78bc-45d3-a1cc-fc959c867373"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Based on animal data, co-administration of Radiogardase with other decorporation agents does not affect the efficacy of Radiogardase for treatment of internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_f88f078f-8e64-4bc2-bd03-deed32244000"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_98d2f598-3a6e-4269-b715-06eb7ac64cd6"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Pregnancy Category C<br></span>It is not known whether Radiogardase can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Animal reproduction studies have not been conducted with prussian blue insoluble. However, since Radiogardase is not absorbed from the gastrointestinal tract, effects on the fetus are not expected. </p>
<p>Radioactive cesium (<span class="Sup">137</span>Cs) crosses the human placenta. One patient, contaminated with 0.005 mCi <span class="Sup">137</span>Cs during her 4<span class="Sup">th</span> month of pregnancy, was not treated with Radiogardase. At birth, the concentration of <span class="Sup">137</span>Cs was the same in the mother and the infant. </p>
<p>Thallium crosses the human placenta. Reported fetal effects include <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The  toxicity from untreated radioactive cesium or thallium exposure is greater than the potential reproductive toxicity of Radiogardase.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_b2b02108-d02f-4a1c-9dd1-a09c172c4488"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies to determine if Radiogardase is excreted in human milk have not been conducted. Since Radiogardase is not absorbed from the gastrointestinal tract, its excretion in milk is unlikely. However, cesium and thallium are transmitted from mother to infant in breast milk. Women internally contaminated with cesium or thallium should not breastfeed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_39d687e5-6c2e-4f59-9f7a-24299bb5f8a1"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span class="Underline">Radioactive Cesium Contamination<br></span>The safety and efficacy of Radiogardase in the treatment of <span class="Sup">137</span>Cs in pediatric patients ages, 2 to 18 years old, was established from data from Radiogardase-treated pediatric patients exposed to <span class="Sup">137</span>Cs in the GoiÃ¢nia, Brazil, contamination incident and from Radiogardase-treated adults exposed to <span class="Sup">137</span>Cs <span class="Italics">[see <a href="#ID_923fb36c-2e47-4740-b735-815068903f14">Clinical Studies (14.1)</a>].</span></p>
<p>Overall, 27 pediatric patients received Radiogardase in the range of 3 to 10 grams per day in divided doses (the maximum recommended adolescent dosage is 9 grams per day). Radiogardase treatment reduced the whole body effective half-life of <span class="Sup">137</span>Cs by 46% in adolescents and by 43% in children aged 4 to 12 years of age. In 12 patients for whom the rate of radiation elimination data are available, the rate was similar to that in adults treated with 3 grams three times daily and in pediatric patients treated with 1 gram three times daily.  By body weight, the dose ranged from </p>
<p>0.32 gram/kg in the 12-year old patient (10 gram Radiogardase daily dose, 31 kg weight) to </p>
<p>0.21 gram/kg in the 4 year old patient (3 gram Radiogardase daily dose, 14 kg weight) <span class="Italics">[see <a href="#ID_923fb36c-2e47-4740-b735-815068903f14">Clinical Studies (14.1)</a>]</span>.</p>
<p>Pediatric patients aged 2 up to 4 years are expected to have biliary and gastrointestinal function that is comparable to that of a 4-year old.  </p>
<p>The safety and efficacy of Radiogardase has not been established in the treatment of <span class="Sup">137</span>Cs contamination in pediatric patients 0 to 2 years old.  There are differences in the developmental maturity of the biliary system and gastrointestinal tract of neonates and infants (0 â€“ 2 years). The dosage-related adverse reactions of Radiogardase on an immature gastrointestinal tract are not known. </p>
<p><span class="Underline">Radioactive and Non-Radioactive Thallium Contamination<br></span>The safety and efficacy of Radiogardase for the treatment of radioactive and non-radioactive thallium contamination in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_bf6b26a1-7729-4ddd-90a1-d233be0c476e"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The safety and efficacy of Radiogardase in patients aged 65 and over have not been evaluated, to determine whether they respond differently from younger subjects.. In general, elderly patients should be monitored closely, reflecting the greater frequency of decreased cardiac function and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_58844d52-3957-428a-bb03-ba1b74b83a2a"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Radiogardase is not systemically bioavailable and does not rely on hepatic metabolism for activation or inactivation. However, Radiogardase may be less effective in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, due to decreased excretion of cesium and thallium in the bile.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_8fffa30a-184c-4dc4-8dfd-9c113629b2a6"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Based on reported adverse reactions and mechanism of action, possible overdosage symptoms may include <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, obstruction, or severe decrease in electrolytes. Gastric distress was reported in 3 patients treated with 20 gram/day of Radiogardase (approximately 2.2 times the maximum recommended dosage).  In these patients, the dose was reduced to 10 gram/day for continued treatment. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_670258af-0933-4160-a8dd-435ed799c6fe"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Radiogardase (prussian blue insoluble) is a decorporation agent for oral use.  Radiogardase capsules contain insoluble ferric hexacyanoferrate(II), with an empirical formula of Fe<span class="Sub">4</span>[Fe(CN)<span class="Sub">6</span>]<span class="Sub">3</span> and a molecular weight of 859.3 Daltons. It is supplied as 0.5 gram of blue powder in gelatin capsules with 0 â€“ 38 mg of microcrystalline cellulose. The dark blue capsule is imprinted with the light blue inscription: <a name="id-1226214953"></a><img alt="Heyl imprint image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-03.jpg"><span class="Sub"></span> PB. The powder may vary from uniformly fine, dark granules to coarse light and dark-colored granules. The structural formula for prussian blue insoluble is shown below.</p>
<div class="Figure">
<a name="id-2018679871"></a><img alt="Structural formula for Prussian blue insoluble" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-02.jpg">
</div>
<p>The crystal structure of prussian blue insoluble is a cubic lattice with the Fe<span class="Sup">II </span>and Fe<span class="Sup">III </span>atoms occupying the corners of the cube and the cyanide groups positioned on the sides.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a029273d-36a6-4c9f-a2a9-7c43e091db0e"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_9b3cdb70-704a-433b-a375-c549b8ac94e3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Prussian blue insoluble, ferric hexacyanoferrate(II), acts by ion-exchange, adsorption, and mechanical trapping within the crystal structure, and has a high affinity for radioactive and non-radioactive cesium and thallium.</p>
<p>Prussian blue insoluble binds cesium and thallium isotopes in the gastrointestinal tract after these isotopes are ingested or excreted in the bile by the liver, thereby reducing gastrointestinal reabsorption (enterohepatic circulation). The rate of cesium and thallium elimination is proportional to the duration and dose of prussian blue insoluble. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_02b16901-33c1-4b8f-83b9-7d7103251d52"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Cesium-137 (<span class="Sup">137</span>Cs)<br></span><span class="Sup">137</span>Cs has a physical half-life of 30 years, with a beta energy peak at 174.0 keV. Following entry into the blood, it is distributed uniformly through all body tissues. Approximately 10% of <span class="Sup">137</span>Cs is eliminated rapidly with a biological half-life of 2 days; 90% is eliminated more slowly, with a biological half-life of 110 days; and less than 1% of the <span class="Sup">137</span>Cs is retained with a biological half-life of about 500 days. <span class="Sup">137</span>Cs follows the movement of potassium and is excreted into the intestine, reabsorbed from the gastrointestinal (GI) tract into the blood, then to the bile, where it is excreted again into the GI tract by bile via enterohepatic circulation. Without Radiogardase treatment, about 80% of <span class="Sup">137</span>Cs is excreted through the kidneys and about 20% in the feces. </p>
<p><span class="Underline">Thallium-201 (<span class="Sup">201</span>Tl)</span><br>Radioactive thallium (<span class="Sup">201</span>Tl) has a physical half-life of 3 days with electron and photon emissions with a gamma energy peak at 167.4 keV. Non-radioactive thallium has a biological half-life of </p>
<p>8 â€“ 10 days.The physiologic transport of thallium follows the same route as potasium and is excreted by bile in enterohepatic circulation. Without Radiogardase treatment, the fecal to urine excretion ratio of thallium is approximately 2:1.</p>
<p>The results of fecal analysis from patients contaminated with <span class="Sup">137</span>Cs and treated with Radiogardase showed higher activities of <span class="Sup">137</span>Cs in feces, and the associated whole body radioactivity counts showed a more rapid rate of elimination from the body. The effectiveness of Radiogardase for one patient is shown in Figure 1. The whole body content of radioactive material of <span class="Sup">137</span>Cs in kilo-Bequerels (kBq) is shown on the y-axis. Time in days is on the x-axis. Line â€œAâ€? represents the whole body activity of <span class="Sup">137</span>Cs during prussian blue insoluble treatment at 10 g/day. The dotted line represents extrapolation of the whole body activity if treatment was continued. Line â€œBâ€? represents the whole body activity of <span class="Sup">137</span>Cs, after prussian blue insoluble was stopped. </p>
<div class="Figure">
<a name="id1748148942"></a><img alt="Figure 1 : Comparisons of 137Cs whole body activity during and after Radiogardase treatment." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-12.jpg">
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_bedf402b-03ae-47ca-b1fa-7e25e6778230"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption/Elimination</span>: <br>Prussian blue insoluble is not absorbed through the intact gastrointestinal wall.  Its clearance from the body depends on the gastrointestinal tract transit time.</p>
<p><span class="Underline">Food Effects</span>:<br>Food effect studies have not been conducted. In animal studies, Prussian blue insoluble was not significantly absorbed. Food may increase the effectiveness of prussian blue insoluble by stimulating bile secretion.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_c20d3213-a9c3-4b6d-a57b-fcff52bb465d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_abaf983d-0532-4132-9320-37570c05e042"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal studies have not been performed to evaluate the carcinogenic or mutagenic potential of prussian blue insoluble.  No study on impairment of male or female fertility and reproductive performance has been conducted in animals.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_447f996c-1086-4864-8e1f-8ff00d185c0e"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Underline">Absorption/Elimination<br></span>In an animal study (pigs, n =38), after a single dose of 40 mg of labeled prussian blue insoluble, 99% of the administered prussian blue dose was excreted unchanged in feces. Absorption from multiple doses has not been studied.</p>
<p>In a study using rats (n = 40, mean body weight range of 188 â€“ 219 grams) injected with <span class="Sup">137</span>Cs, a dose response relationship was demonstrated for the amount of radiation elimination with prussian blue insoluble at doses of 1 to 50 mg/day (Table 1). There is little difference in radiation elimination rate between prussian blue insoluble at doses of 50 to 100 mg/day. In Table 1, the % of Injected Radiation Dose Remaining is defined as the percentage of the total injected dose of <span class="Sup">137</span>Cs remaining in the body at 96 hours post administration.</p>
<table width="70%">
<col width="28%">
<col width="53%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Table 1: Dose Response Relationship in Rats at 96 Hours</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Prussian blue insoluble dose (mg/day)</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"> % Injected <span class="Sup">137</span>Cs dose remaining (Range) </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Untreated</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">58.1	(63.3 â€“ 53.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.42	(13.2 â€“ 6.72)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.17	(1.64 â€“ 0.84)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.57	(0.80 â€“ 0.41)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.52	(0.73 â€“ 0.37)</p></td>
</tr>
</tbody>
</table>
<p>In studies of rats, pigs, and dogs that were internally contaminated with cesium and thallium, the presence of the insoluble complexes in the gastrointestinal lumen changed the primary elimination route from the kidney to the feces and increased the rate of elimination of these two contaminants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_348809b2-e46a-453f-9642-e6b56b6d7a31"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_923fb36c-2e47-4740-b735-815068903f14"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Cesium-137 Contamination</h2>
<p class="First">In literature reports, 72 people received Radiogardase after exposure to radioactive cesium (<span class="Sup">137</span>Cs):</p>
<dl>
<dt>â€¢</dt>
<dd>46 patients with 137Cs contamination </dd>
<dt>â€¢</dt>
<dd>19 patients 137Cs contamination in other incidents</dd>
<dt>â€¢</dt>
<dd>7 healthy human subjects who voluntarily ingested trace doses of 137Cs</dd>
</dl>
<p>In a 1987 incident in GoiÃ¢nia, Brazil, 46 patients with heavy internal contamination with 137Cs were treated with Radiogardase (Table 2).  Data on the whole body effective half-life of 137Cs, during and after Radiogardase treatment, was completed on 33 of these 46 patients (see Table 2). Radiogardase reduced the mean whole-body effective half-life of 137Cs by 69%, 46%, and 43% in adults, adolescents, and  younger children, respectively.  </p>
<p>Table 2 shows the decrease in whole body effective half-life of 137Cs in patients during Radiogardase treatment compared to the half-life of 137Cs after Radiogardase discontinuation (after treatment).</p>
<table width="90.28%">
<col width="21%">
<col width="10%">
<col width="23%">
<col width="20%">
<col width="26%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Table 2: Cesium-137 Effective Half-life During and After Treatment with Radiogardase</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle">
<p class="First"><span class="Bold">Age</span></p>
<p><span class="Bold">(years)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Radiogardase Dosage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold"><span class="Sup">137</span>Cs Effective Half Life</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">During <br>Radiogardase Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">After Radiogardase Treatment</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Adults (n=5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="middle"><p class="First">&gt; 18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10 grams/day</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26 Â± 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="middle">
<p class="First">80 Â± 15 days</p>
<p>(all 21 adult patients)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Adults (n=10)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 grams/day</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25 Â± 15 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Adults (n=6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 grams/day</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25 Â± 9 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Adolescents (n=5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12 -14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;	10 grams/day</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30 Â± 12 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">62 Â± 14 days</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Â Children (n=7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 â€“ 9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;	3 grams/day</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24 Â± 3 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">42 Â± 4 days</p></td>
</tr>
</tbody>
</table>
<p>Data from additional literature articles including 19 patients contaminated with <span class="Sup">137</span>Cs in other incidents and a study of 7 human subjects who voluntarily ingested trace doses of <span class="Sup">137</span>Cs showed a similar reduction in whole body effective half-life with Radiogardase treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c01dbc04-1f9c-4773-ba3f-db60097bc3f8"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Thallium Contamination</h2>
<p class="First">Thirty-four patients treated with Radiogardase for non-radioactive thallium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> have been reported in the literature. Radiogardase treatment reduced the mean serum biologic half-life of thallium from 8 days to 3 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_02f4582e-c520-4fdd-b46e-9a4028042bb8"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Radiogardase is supplied as gelatin capsules containing 0.5 grams of prussian blue insoluble for oral administration. The dark blue capsule is imprinted with the light blue inscription: <a name="id594984322"></a><img alt="Heyl imprint image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-06.jpg"><span class="Sub"></span>PB. It is packaged in white plastic containers with a child-resistant tamper-evident closure. Each container contains 36 capsules. </p>
<dl>
<dt>â€¢</dt>
<dd>NDC:  58060-002-02</dd>
</dl>
<p><span class="Bold">Storage</span></p>
<p>Store at 20 Â°C to 25 Â°C (68 Â°F to 77 Â°F), excursions permitted between 15 Â°C and 30Â°C (between 59 Â°F and 86 Â°F). Brief exposure to temperatures up to 40 Â°C (104 Â°F) may be tolerated, provided the mean kinetic temperature does not exceed 25 Â°C (77 Â°F); however, minimize such exposure. [see USP Controlled Room Temperature]</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_ea62bf51-2101-4356-819d-2052a3fea89c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">Decreased Gastrointestinal Motility<br></span>Inform patients that Radiogardase can decrease gastrointestinal motility. This can slow the transit time of cesium or thallium bound to Radiogardase and increase the radiation absorbed dose to the gastrointestinal mucosa. Alert patients to monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and advise patients to seek medical management if symptoms develop. </p>
<p><span class="Bold">Precautions to Mitigate <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">Radiation Exposure</span><br></span>Inform patients of safety measures to be taken to minimize <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> to others or re-exposure to self. This includes instruction on appropriate use of the toilet, hand washing, and handling of items such as clothing that might get contaminated with body fluids. </p>
<p><span class="Bold">Discoloration of Stool, Oral Mucosa and Dentition<br></span>Inform patients taking Radiogardase that their stools might be blue-colored. Also inform patients that if the Radiogardase capsules are opened and the contents are mixed with food and eaten, the mouth and teeth may be colored blue.</p>
<p>Manufactured by:<br>Haupt Pharma <br>Berlin GmbH </p>
<p>Distribution by:<br>HEYL Chemisch-pharmazeutische <br>Fabrik GmbH &amp; Co. KG, <br>Berlin</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7552f4bb-da9f-443f-adaf-7dea4d0e9468"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id814"></a><img alt="Box Radiogardase36" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-04.jpg">
</div>
<div class="Figure">
<a name="id816"></a><img alt="Label Radiogardase36" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&amp;name=image-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RADIOGARDASEÂ 		
					</strong><br><span class="contentTableReg">prussian blue insoluble capsules capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58060-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FERRIC FERROCYANIDE</strong> (FERRIC FERROCYANIDE) </td>
<td class="formItem">FERRIC FERROCYANIDE</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">38Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">83.12Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">14.21Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">0.67Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">0.15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (Heyl;PB) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Heyl;PB) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Heyl;PB</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58060-002-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">36  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021626</td>
<td class="formItem">03/24/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Heyl Chem.-pharm. Fabrik GmbH &amp; Co. KG
							(317151645)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Heyl Chem.-pharm. Fabrik GmbH &amp; Co. KG (317151645)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Haupt Pharma Berlin GmbH</td>
<td class="formItem"></td>
<td class="formItem">316070416</td>
<td class="formItem">MANUFACTURE(58060-002)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laborchemie Apolda GmbH</td>
<td class="formItem"></td>
<td class="formItem">331821462</td>
<td class="formItem">API MANUFACTURE(58060-002)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>39b323b1-0ce6-460f-8204-33eafb74a788</div>
<div>Set id: baa68c79-5f3d-468a-a510-58b9e978cd50</div>
<div>Version: 5</div>
<div>Effective Time: 20140911</div>
</div>
</div>Â <div class="DistributorName">Heyl Chem.-pharm. Fabrik GmbH &amp; Co. KG</div></p>
</body></html>
